{"id":"W2024797586","doi":"10.1016/j.bbmt.2013.08.013","title":"Providing Personalized Prognostic Information for Adult Leukemia Survivors","year":2013,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Takeda Oncology; Health Resources and Services Administration; National Institutes of Health; Therakos; Sigma-Tau Pharmaceuticals; Kiadis Pharma; Genentech; CellGenix; Medical College of Wisconsin; Tarix Pharmaceuticals; StemCyte; Blue Cross and Blue Shield Association; Swedish Orphan Biovitrum; Amgen; Otsuka America Pharmaceutical; Teva Pharmaceutical Industries; WellPoint; HistoGenetics; Otsuka America; U.S. Navy; Osiris Therapeutics; Celgene; Ariad Pharmaceuticals; GlaxoSmithKline; U.S. Department of Defense; Sanofi; Be The Match Foundation","keywords":"Medicine; Myeloid leukemia; Internal medicine; Transplantation; Hematopoietic stem cell transplantation; Leukemia; Disease; Oncology; Chronic leukemia; Graft-versus-host disease; Immunology; Acute leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001209704,0.000327808,0.0004981186,0.001680049,0.0001702863,0.0006231694,0.0003080005,0.0003660579,0.002817716],"category_scores_gemma":[0.006685943,0.0001543787,0.0002895418,0.001702288,0.0001008118,0.0008160208,0.0005772735,0.0004897362,0.0006645027],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002514561,"about_ca_system_score_gemma":0.000309361,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001097677,"about_ca_topic_score_gemma":0.001802629,"domain_scores_codex":[0.9995145,0.0002597695,0.00005131886,0.00005137282,0.00007314695,0.00004988598],"domain_scores_gemma":[0.9980991,0.0009771171,0.0004096633,0.0001932606,0.0001918254,0.0001290412],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004755081,0.00008320957,0.6876917,0.00006737308,0.00009927797,0.0002177875,0.0001452091,0.003974021,0.0007071121,0.0005620518,0.006096749,0.2998801],"study_design_scores_gemma":[0.0002340061,0.0008584774,0.8796126,0.0003297407,0.0007722771,0.002371736,0.0005888152,0.05800884,0.005644628,0.0133682,0.03808953,0.0001211424],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"methods","genre_scores_codex":[0.9263544,0.007310615,0.03952328,0.004649192,0.0001132215,0.0001669043,0.01380121,0.001198402,0.006882731],"genre_scores_gemma":[0.9705512,0.002202525,0.01960213,0.0003206472,0.0002003673,0.00007607401,0.006341623,0.00003641792,0.0006691353],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.002817716,"threshold_uncertainty_score":0.009426236,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01152013772410259,"score_gpt":0.2566126272903693,"score_spread":0.2450924895662667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}